Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.57 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28928924 | 1.00 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL27680742 | 0.94 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL1000056 | 0.92 | MDM2 (0.55) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL28124458 | 0.90 | MDM2 (0.58) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29851790 | 0.90 | MDM2 (0.58) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL16059779 | 0.90 | MDM2 (0.58) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL1740478 | 0.90 | MDM2 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL28306682 | 0.89 | MDM4 (0.52) | MDM2MDM4TP53CASP3IDO1 | |
| SCHEMBL14920476 | 0.89 | MDM2 (0.55) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL5416538 | 0.87 | SLC17A5 (0.51) | MDM2MDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115583989-B | SSTR 2-targeted compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-02-28 | — | — | CN | claimed |
| CN-115583989-A | SSTR 2-targeted compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-01-10 | — | — | CN | claimed |
| CN-115583989-B | SSTR 2-targeted compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-115583989-A | SSTR 2-targeted compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-01-10 | — | — | CN | disclosed |
| EP-3185908-A1 | STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | Pfizer Inc (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030791-A1 | STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES | PFIZER INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-6723699-B1 | ADMINISTERING AS CHOLINERGIC AGENT TO TREAT NERVOUS SYSTEM DISORDERS | CEPHALON, INC. | 2004-04-20 | — | — | US | disclosed |
| US-6693076-B1 | ENHANCING SURVIVAL OF NEURONAL CELLS AT RISK OF DYING DUE TO INJURY OR EPILEPSY | CEPHALON, INC. | 2004-02-17 | — | — | US | disclosed |
| US-6310040-B1 | FOR PROMOTING THE SURVIVAL OF PHOTORECEPTORS IN A MAMMAL | CEPHALON, INC. | 2001-10-30 | — | — | US | disclosed |
| US-5776897-A | Treating disorders by application of insulin-like growth factors and analogs | CEPHALON, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5703045-A | NERVOUS SYSTEM DISORDERS | CEPHALON, INC. (US) | 1997-12-30 | — | — | US | disclosed |
| US-5652214-A | ENHANCING SURVIVAL OF NEURONAL CELLS IN HEAD AND SPINAL CORD AFTER INJURY, ALSO TREATMENT OF AGING, ALZHEIMER*S, STROKE, EPILEPSY | CEPHALON, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| EP-0604605-A4 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0670729-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0670729-A4 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS. | CEPHALON INC (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0604605-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993020836-A1 | TREATING DISORDERS BY APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993008826-A1 | TREATING RETINAL NEURONAL DISORDERS BY THE APPLICATION OF INSULIN-LIKE GROWTH FACTORS AND ANALOGS | CEPHALON, INC. (US) | 1993-05-13 | — | — | WO | disclosed |